ArticleBlood2011
Heparin promotes platelet responsiveness by potentiating αIIbβ3-mediated outside-in signaling.
Article in Blood, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 127 citations in OpenAlex.
- Hemocompatibility of Mechanical Circulatory Support Devices: An Integrated Review of Platelet Function Assessment in In-Vitro Blood Experiments.Annals of biomedical engineering · 2026Pooled it
- Trial
- Platelets are dominant contributors to hypercoagulability after injury.The journal of trauma and acute care surgery · 2013Trial
- Trial
- Fully Synthetic Non-Carbohydrate Heparin Mimetics-Perspectives for Therapeutic Anticoagulation and Beyond?Archiv der Pharmazie · 2026Review
- Impact of Pre-PCI Activated Clotting Time on Outcomes of Bivalirudin Versus Heparin During Primary PCI.Journal of the Society for Cardiovascular Angiography & Interventions · 2025Article
- Reversible Platelet Aggregation Induced by Low-Temperature Storage in Heparinized Whole Blood Samples.Hematology reports · 2025Article
- Genetic association of preeclampsia to von Willebrand factor and its size-regulator ADAMTS13.Research square · 2025Article
- Impact of sampling technique, anticoagulant, processing delay, and temperature on murine platelet function in whole blood.Research and practice in thrombosis and haemostasis · 2025Article
- Monocyte-Platelet Aggregates Are Major Source of BDNF after Bacterial Stimulation of Human Peripheral Blood Immune Cells.European journal of immunology · 2025Article
- Unfractionated heparin reverses aspirin inhibition of platelets during coronary artery bypass graft surgery.Scientific reports · 2024Article
- Intravenous enoxaparin as alternative ECMO anticoagulation over a period of 94 days: a case report.Journal of cardiothoracic surgery · 2023Article
- Anticoagulation for cardiopulmonary bypass: part one.BJA education · 2023Review
- Platelets and Their Role in Hemostasis and Thrombosis-From Physiology to Pathophysiology and Therapeutic Implications.International journal of molecular sciences · 2022Review
- Review
- Ex vivo anticoagulants affect human blood platelet biomechanics with implications for high-throughput functional mechanophenotyping.Communications biology · 2022Article
- Hemostatic Effect of 20(S)-Panaxadiol by Induced Platelet Aggregation Depending on Calcium Signaling Pathway.BioMed research international · 2022Article
- Validation of a Miniaturized Test Loop for the Assessment of Human Blood Damage by Continuous-Flow Left-Ventricular Assist Devices.Annals of biomedical engineering · 2021Article
- Durable endothelium-mimicking coating for surface bioengineering cardiovascular stents.Bioactive materials · 2021Article
- mTOR regulates GPVI-mediated platelet activation.Journal of translational medicine · 2021Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Unfractionated heparin (UFH) is a widely used anticoagulant that has long been known to potentiate platelet responses to subthreshold doses of platelet agonists. UFH has been reported to bind and induce modest conformational changes in the major platelet integrin, αIIbβ3, and induce minor changes in platelet morphology. The mechanism by which UFH elicits these platelet-activating effects, however, is not well understood. We found that both human and murine platelets exposed to UFH, either in solution or immobilized onto artificial surfaces, underwent biochemical and morphologic changes indicative of a potentiated state, including phosphorylation of key cytosolic signaling molecules and cytoskeletal changes leading to cell spreading. Low molecular weight heparin and the synthetic pentasaccharide, fondaparinux, had similar platelet-potentiating effects. Human or mouse platelets lacking functional integrin αIIbβ3 complexes and human platelets pretreated with the fibrinogen receptor antagonists eptifibatide or abciximab failed to become potentiated by heparin, demonstrating that heparin promotes platelet responsiveness via its ability to initiate αIIbβ3-mediated outside-in signaling. Taken together, these data provide novel insights into the mechanism by which platelets become activated after exposure to heparin and heparin-coated surfaces, and suggest that currently used glycoprotein IIb-IIIa inhibitors may be effective inhibitors of nonimmune forms of heparin-induced platelet activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.